Manning 's most recent trade in Liquidia Corp was a trade of 5,882 Common Stock done . Disclosure was reported to the exchange on June 16, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Liquidia Corp | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2026 | 5,882 | 475,465 (1%) | 0% | 0 | Common Stock | |
| Monte Rosa Therapeutics Inc | Anthony M. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 25,800 | 25,800 | - | - | Stock Option (Right to Buy) | |
| Liquidia Corp | Paul B. Manning | Director | Sale of securities on an exchange or to another person at price $ 64.28 per share. | 04 Jun 2026 | 88,487 | 716,311 (2%) | 0% | 64.3 | 5,687,944 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Sale of securities on an exchange or to another person at price $ 63.83 per share. | 04 Jun 2026 | 68,265 | 810,945 (2%) | 0% | 63.8 | 4,357,355 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Sale of securities on an exchange or to another person at price $ 62.62 per share. | 04 Jun 2026 | 19,125 | 879,210 (3%) | 0% | 62.6 | 1,197,608 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Sale of securities on an exchange or to another person at price $ 64.42 per share. | 04 Jun 2026 | 12,610 | 798,335 (2%) | 0% | 64.4 | 812,336 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Sale of securities on an exchange or to another person at price $ 63.13 per share. | 04 Jun 2026 | 11,513 | 804,798 (2%) | 0% | 63.1 | 726,816 | Common Stock |
| Monte Rosa Therapeutics Inc | Anthony M. Manning | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2026 | 10,000 | 12,100 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Anthony M. Manning | Director | Sale of securities on an exchange or to another person at price $ 18.01 per share. | 21 May 2026 | 10,000 | 0 | - | 18.0 | 180,100 | Common Stock |
| Monte Rosa Therapeutics Inc | Anthony M. Manning | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.16 per share. | 21 May 2026 | 10,000 | 10,000 | - | 4.2 | 41,600 | Common Stock |
| Vistance Networks Inc | Thomas J. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2026 | 16,807 | 177,797 (0%) | 0% | 0 | Common Stock | |
| Candel Therapeutics Inc | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2026 | 4,618 | 4,618 | - | - | Stock Option (Right to Buy) | |
| Business First Bancshares Inc | Kathryn Manning | EVP & Chief Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.04 per share. | 31 Mar 2026 | 874 | 15,791 (0%) | 0% | 27.0 | 23,633 | COMMON STOCK |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 30.04 per share. | 27 Mar 2026 | 4,864 | 67,165 (0%) | 0% | 30.0 | 146,100 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 31.04 per share. | 27 Mar 2026 | 2,100 | 65,065 (0%) | 0% | 31.0 | 65,181 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 31.72 per share. | 27 Mar 2026 | 558 | 64,507 (0%) | 0% | 31.7 | 17,699 | Common Stock |
| Array Tech Inc | Neil Manning | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2026 | 20,391 | 40,783 | - | - | Restricted Stock Units | |
| Array Tech Inc | Neil Manning | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2026 | 20,391 | 59,400 | - | - | Common Stock, par value $0.001 per share | |
| Array Tech Inc | Neil Manning | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.86 per share. | 17 Mar 2026 | 5,475 | 53,925 | - | 6.9 | 37,559 | Common Stock, par value $0.001 per share |
| Array Tech Inc | Neil Manning | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2026 | 4,882 | 40,320 | - | - | Common Stock, par value $0.001 per share | |
| Array Tech Inc | Neil Manning | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2026 | 4,882 | 0 | - | - | Restricted Stock Units | |
| Array Tech Inc | Neil Manning | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.99 per share. | 17 Mar 2026 | 1,311 | 39,009 | - | 7.0 | 9,164 | Common Stock, par value $0.001 per share |
| Array Tech Inc | Neil Manning | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2026 | 41,299 | 41,299 | - | - | Restricted Stock Units | |
| Array Tech Inc | Neil Manning | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 8,217 | 38,049 | - | - | Common Stock, par value $0.001 per share | |
| Array Tech Inc | Neil Manning | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 8,217 | 8,217 | - | - | Restricted Stock Units | |
| Array Tech Inc | Neil Manning | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.80 per share. | 12 Mar 2026 | 2,611 | 35,438 | - | 6.8 | 17,755 | Common Stock, par value $0.001 per share |
| Business First Bancshares Inc | Kathryn Manning | EVP & Chief Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2026 | 2,984 | 8,641 | - | - | Restricted Stock Units | |
| Business First Bancshares Inc | Kathryn Manning | EVP & Chief Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 1,239 | 17,904 (0%) | 0% | - | COMMON STOCK | |
| Business First Bancshares Inc | Kathryn Manning | EVP & Chief Risk Officer | Sale or transfer of securities back to the company at price $ 27.30 per share. | 01 Mar 2026 | 1,239 | 16,665 (0%) | 0% | 27.3 | 33,825 | COMMON STOCK |
| Business First Bancshares Inc | Kathryn Manning | EVP & Chief Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 1,239 | 4,912 | - | - | Restricted Stock Units | |
| Business First Bancshares Inc | Kathryn Manning | EVP & Chief Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2026 | 745 | 5,657 | - | - | Restricted Stock Units | |
| Candel Therapeutics Inc | Paul B. Manning | Director | Purchase of securities on an exchange or from another person at price $ 5.45 per share. | 23 Feb 2026 | 550,458 | 2,763,527 | - | 5.4 | 2,999,996 | Common Stock |
| Array Tech Inc | Neil Manning | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2026 | 3,749 | 31,038 | - | - | Common Stock, par value $0.001 per share | |
| Array Tech Inc | Neil Manning | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2026 | 3,749 | 0 | - | - | Restricted Stock Units | |
| Array Tech Inc | Neil Manning | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.29 per share. | 15 Feb 2026 | 1,206 | 29,832 | - | 11.3 | 13,616 | Common Stock, par value $0.001 per share |
| Sensient Tech Corp | Paul Manning | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 30,027 | 0 | - | - | Performance Stock Unit | |
| Sensient Tech Corp | Paul Manning | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 30,027 | 290,967 (0%) | 0% | 0 | Common Stock | |
| Sensient Tech Corp | Paul Manning | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 97.93 per share. | 12 Feb 2026 | 15,013 | 275,954 (0%) | 0% | 97.9 | 1,470,223 | Common Stock |
| Sensient Tech Corp | John J. Manning | SVP, GC & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 4,016 | 37,208 (0%) | 0% | 0 | Common Stock | |
| Sensient Tech Corp | John J. Manning | SVP, GC & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 4,016 | 0 | - | - | Performance Stock Unit | |
| Sensient Tech Corp | John J. Manning | SVP, GC & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 97.93 per share. | 12 Feb 2026 | 2,008 | 35,200 (0%) | 0% | 97.9 | 196,643 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Other type of transaction at price $ 42.63 per share. | 11 Feb 2026 | 55,116 | 469,583 (1%) | 0% | 42.6 | 2,349,595 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Other type of transaction at price $ 42.63 per share. | 11 Feb 2026 | 55,116 | 0 (0%) | 0% | 42.6 | 2,349,595 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2026 | 32,800 | 32,800 | - | - | Employee stock option (right to buy) | |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2026 | 28,600 | 72,029 (0%) | 0% | 0 | Common Stock | |
| White Mountains Insurance Grp Ltd | George Manning Rountree | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2050.00 per share. | 19 Dec 2025 | 5,000 | 13,809 (0%) | 0% | 2050 | 10,250,000 | Common Shares |
| Sensient Tech Corp | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 29,516 | 29,516 | - | - | Performance Stock Unit | |
| Sensient Tech Corp | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 19,677 | 260,940 (0%) | 0% | 0 | Common Stock | |
| Sensient Tech Corp | John J. Manning | SVP, GC & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 4,195 | 4,195 | - | - | Performance Stock Unit | |
| Sensient Tech Corp | John J. Manning | SVP, GC & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 2,796 | 33,192 (0%) | 0% | 0 | Common Stock | |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 49.95 per share. | 15 Dec 2025 | 1,922 | 43,429 (0%) | 0% | 50.0 | 96,004 | Common Stock |
| Business First Bancshares Inc | Kathryn Manning | EVP & Chief Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2025 | 1,179 | 17,082 (0%) | 0% | - | COMMON STOCK | |
| Business First Bancshares Inc | Kathryn Manning | EVP & Chief Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2025 | 1,179 | 6,151 | - | - | Restricted Stock Units | |
| Business First Bancshares Inc | Kathryn Manning | EVP & Chief Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.71 per share. | 12 Dec 2025 | 417 | 16,665 (0%) | 0% | 27.7 | 11,555 | COMMON STOCK |
| Sensient Tech Corp | Paul Manning | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.02 per share. | 08 Dec 2025 | 11,720 | 241,263 (0%) | 0% | 90.0 | 1,055,034 | Common Stock |
| Sensient Tech Corp | John J. Manning | SVP, GC & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.02 per share. | 08 Dec 2025 | 1,567 | 30,396 (0%) | 0% | 90.0 | 141,061 | Common Stock |
| Verrica Pharma Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 4.24 per share. | 25 Nov 2025 | 2,750,762 | 3,348,372 (12%) | 10% | 4.2 | 11,670,108 | Common Stock |
| Verrica Pharma Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 4.24 per share. | 25 Nov 2025 | 1,375,380 | 3,958,189 (15%) | 5% | 4.2 | 5,835,050 | Common Stock |
| Verrica Pharma Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 25 Nov 2025 | 687,690 | 687,690 | - | - | Series C Warrant (right to buy) | |
| Verrica Pharma Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 25 Nov 2025 | 343,845 | 343,845 | - | - | Series C Warrant (right to buy) | |
| Olo Inc (Class A) | Sherri Manning | Chief People Officer | Sale of securities on an exchange or to another person at price $ 10.25 per share. | 05 Sep 2025 | 5,608 | 292,318 | - | 10.3 | 57,507 | Class A Common Stock |
| Johnson Controls | Nathan D. Manning | VP and President, Americas | Sale of securities on an exchange or to another person at price $ 105.06 per share. | 02 Sep 2025 | 1,422 | 139,458 (0%) | 0% | 105.1 | 149,395 | Ordinary Shares |
| Liquidia Corp | Paul B. Manning | Director | Sale of securities on an exchange or to another person at price $ 28.67 per share. | 28 Aug 2025 | 254,038 | 505,058 (1%) | 0% | 28.7 | 7,283,269 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Sale of securities on an exchange or to another person at price $ 27.62 per share. | 28 Aug 2025 | 188,232 | 759,096 (2%) | 0% | 27.6 | 5,198,968 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Sale of securities on an exchange or to another person at price $ 27.94 per share. | 28 Aug 2025 | 154,337 | 947,328 (3%) | 0% | 27.9 | 4,312,176 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Sale of securities on an exchange or to another person at price $ 29.14 per share. | 28 Aug 2025 | 74,230 | 430,828 (1%) | 0% | 29.1 | 2,163,062 | Common Stock |
| Sensient Tech Corp | Paul Manning | Director, Chairman, President & CEO | Purchase of securities on an exchange or from another person at price $ 116.95 per share. | 11 Aug 2025 | 20 | 80 (0%) | 0% | 117.0 | 2,339 | Common Stock |
| Johnson Controls | Nathan D. Manning | VP and President, Americas | Sale of securities on an exchange or to another person at price $ 103.69 per share. | 01 Aug 2025 | 1,422 | 140,880 (0%) | 0% | 103.7 | 147,447 | Ordinary Shares |
| Johnson Controls | Nathan D. Manning | VP and President, Americas | Sale of securities on an exchange or to another person at price $ 104.56 per share. | 01 Jul 2025 | 1,022 | 142,260 (0%) | 0% | 104.6 | 106,860 | Ordinary Shares |
| Johnson Controls | Nathan D. Manning | VP and President, Americas | Sale of securities on an exchange or to another person at price $ 105.48 per share. | 01 Jul 2025 | 400 | 141,860 (0%) | 0% | 105.5 | 42,192 | Ordinary Shares |
| Candel Therapeutics Inc | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 4.67 per share. | 25 Jun 2025 | 1,070,663 | 2,213,069 | - | 4.7 | 4,999,996 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 18,396 | 38,755 (0%) | 0% | 0 | Common Stock | |
| Candel Therapeutics Inc | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 14,240 | 14,240 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Anthony M. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2025 | 30,700 | 30,700 | - | - | Stock Option (Right to Buy) | |
| Olo Inc (Class A) | Sherri Manning | Chief People Officer | Sale of securities on an exchange or to another person at price $ 8.80 per share. | 05 Jun 2025 | 5,657 | 297,926 | - | 8.8 | 49,770 | Class A Common Stock |
| Johnson Controls | Nathan D. Manning | VP and President, Americas | Sale of securities on an exchange or to another person at price $ 100.90 per share. | 02 Jun 2025 | 1,422 | 143,282 (0%) | 0% | 100.9 | 143,480 | Ordinary Shares |
| Taysha Gene Therapies Inc | Paul B. Manning | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.75 per share. | 30 May 2025 | 750,000 | 2,841,704 | - | 2.8 | 2,062,500 | Common Stock |
| Vistance Networks Inc | Thomas J. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 40,000 | 160,990 (0%) | 0% | 0 | Common Stock | |
| Johnson Controls | Manning Nathan D. | VP and President, Americas | Sale of securities on an exchange or to another person at price $ 86.77 per share. | 01 May 2025 | 822 | 145,104 (0%) | 0% | 86.8 | 71,325 | Ordinary Shares |
| Johnson Controls | D. Manning Nathan | VP and President, Americas | Sale of securities on an exchange or to another person at price $ 88.09 per share. | 01 May 2025 | 400 | 144,704 (0%) | 0% | 88.1 | 35,236 | Ordinary Shares |
| Johnson Controls | D. Manning Nathan | VP and President, Americas | Sale of securities on an exchange or to another person at price $ 85.16 per share. | 01 May 2025 | 200 | 145,926 (0%) | 0% | 85.2 | 17,032 | Ordinary Shares |
| Johnson Controls | Nathan D. Manning | VP, President BSNA | Sale of securities on an exchange or to another person at price $ 79.72 per share. | 01 Apr 2025 | 1,422 | 145,502 (0%) | 0% | 79.7 | 113,362 | Ordinary Shares |
| Business First Bancshares Inc | Kathryn Manning | EVP & Chief Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.35 per share. | 31 Mar 2025 | 1,989 | 15,903 (0%) | 0% | 24.3 | 48,432 | COMMON STOCK |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 46.31 per share. | 27 Mar 2025 | 37,000 | 82,351 (0%) | 0% | 46.3 | 1,713,470 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 67.04 per share. | 27 Mar 2025 | 37,000 | 45,351 (0%) | 0% | 67.0 | 2,480,436 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2025 | 37,000 | 91,000 | - | - | Employee stock option (right to buy) | |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 68.79 per share. | 27 Mar 2025 | 2,599 | 47,270 (0%) | 0% | 68.8 | 178,780 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 67.70 per share. | 27 Mar 2025 | 1,976 | 49,869 (0%) | 0% | 67.7 | 133,777 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 69.84 per share. | 27 Mar 2025 | 1,505 | 45,765 (0%) | 0% | 69.8 | 105,105 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 66.79 per share. | 27 Mar 2025 | 1,087 | 51,845 (0%) | 0% | 66.8 | 72,602 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 65.97 per share. | 27 Mar 2025 | 668 | 52,932 (0%) | 0% | 66.0 | 44,067 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 71.74 per share. | 27 Mar 2025 | 225 | 45,385 (0%) | 0% | 71.7 | 16,142 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 70.74 per share. | 27 Mar 2025 | 155 | 45,610 (0%) | 0% | 70.7 | 10,964 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 72.65 per share. | 27 Mar 2025 | 34 | 45,351 (0%) | 0% | 72.6 | 2,470 | Common Stock |
| Array Tech Inc | Neil Manning | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2025 | 61,174 | 150,176 | - | - | Restricted Stock Units | |
| Array Tech Inc | Neil Manning | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2025 | 4,882 | 145,294 | - | - | Restricted Stock Units | |
| Array Tech Inc | Neil Manning | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2025 | 4,882 | 26,863 | - | 0 | Common Stock, par value $0.001 per share | |
| Array Tech Inc | Neil Manning | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.10 per share. | 17 Mar 2025 | 1,311 | 25,552 | - | 6.1 | 7,997 | Common Stock, par value $0.001 per share |
| Array Tech Inc | Neil Manning | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 8,216 | 89,002 | - | - | Restricted Stock Units | |
| Array Tech Inc | Neil Manning | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 8,216 | 24,187 | - | 0 | Common Stock, par value $0.001 per share | |
| Array Tech Inc | Neil Manning | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.03 per share. | 12 Mar 2025 | 2,206 | 21,981 | - | 6.0 | 13,302 | Common Stock, par value $0.001 per share |